Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies

Abstract Since the introduction of leukemia-type induction therapies for T-cell lymphoblastic lymphoma (T-LBL), improvements in the long-term outcomes of T-LBL have been reported. However, indications for and the appropriate timing of hematopoietic stem cell transplantation (HSCT) have not yet been...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mari Morita-Fujita, Yasuyuki Arai, Satoshi Yoshioka, Takayuki Ishikawa, Junya Kanda, Tadakazu Kondo, Takashi Akasaka, Yasunori Ueda, Kazunori Imada, Toshinori Moriguchi, Kazuhiro Yago, Toshiyuki Kitano, Akihito Yonezawa, Masaharu Nohgawa, Akifumi Takaori-Kondo, Kyoto Stem Cell Transplantation Group (KSCTG)
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/33bb1f49f6f144e8930823840ad60891
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33bb1f49f6f144e8930823840ad60891
record_format	dspace
spelling	oai:doaj.org-article:33bb1f49f6f144e8930823840ad608912021-12-02T12:33:15ZIndication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies10.1038/s41598-020-78334-x2045-2322https://doaj.org/article/33bb1f49f6f144e8930823840ad608912020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78334-xhttps://doaj.org/toc/2045-2322Abstract Since the introduction of leukemia-type induction therapies for T-cell lymphoblastic lymphoma (T-LBL), improvements in the long-term outcomes of T-LBL have been reported. However, indications for and the appropriate timing of hematopoietic stem cell transplantation (HSCT) have not yet been established. Therefore, we performed a multicenter retrospective cohort study of patients with T-LBL treated using leukemia-type initial therapies to compare the outcomes after HSCT at different disease stages. We enrolled 21 patients with T-LBL from a total of 11 centers, and all patients received hyper-CVAD as a leukemia-type initial regimen. HSCT was performed during the CR1/PR1 (standard disease) stage in 11 patients, while it was completed at a later or non-remission (advanced disease) stage in 10 patients. Following HSCT, the overall survival rate was significantly greater in standard disease than in advanced-disease patients (79.5% vs. 30.0% at 5 years; hazard ratio (HR) 5.97; p = 0.03), with trend to the lower incidence of relapse in the former group (27.3% vs. 60.0% at 5 years; HR 2.29; p = 0.19). A prognostic difference was not detected between cases treated with allogeneic and autologous HSCTs. Our study suggests that frontline HSCT may be a feasible treatment option for T-LBL, even in the era of leukemia-type initial therapy.Mari Morita-FujitaYasuyuki AraiSatoshi YoshiokaTakayuki IshikawaJunya KandaTadakazu KondoTakashi AkasakaYasunori UedaKazunori ImadaToshinori MoriguchiKazuhiro YagoToshiyuki KitanoAkihito YonezawaMasaharu NohgawaAkifumi Takaori-KondoKyoto Stem Cell Transplantation Group (KSCTG)Nature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mari Morita-Fujita Yasuyuki Arai Satoshi Yoshioka Takayuki Ishikawa Junya Kanda Tadakazu Kondo Takashi Akasaka Yasunori Ueda Kazunori Imada Toshinori Moriguchi Kazuhiro Yago Toshiyuki Kitano Akihito Yonezawa Masaharu Nohgawa Akifumi Takaori-Kondo Kyoto Stem Cell Transplantation Group (KSCTG) Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
description	Abstract Since the introduction of leukemia-type induction therapies for T-cell lymphoblastic lymphoma (T-LBL), improvements in the long-term outcomes of T-LBL have been reported. However, indications for and the appropriate timing of hematopoietic stem cell transplantation (HSCT) have not yet been established. Therefore, we performed a multicenter retrospective cohort study of patients with T-LBL treated using leukemia-type initial therapies to compare the outcomes after HSCT at different disease stages. We enrolled 21 patients with T-LBL from a total of 11 centers, and all patients received hyper-CVAD as a leukemia-type initial regimen. HSCT was performed during the CR1/PR1 (standard disease) stage in 11 patients, while it was completed at a later or non-remission (advanced disease) stage in 10 patients. Following HSCT, the overall survival rate was significantly greater in standard disease than in advanced-disease patients (79.5% vs. 30.0% at 5 years; hazard ratio (HR) 5.97; p = 0.03), with trend to the lower incidence of relapse in the former group (27.3% vs. 60.0% at 5 years; HR 2.29; p = 0.19). A prognostic difference was not detected between cases treated with allogeneic and autologous HSCTs. Our study suggests that frontline HSCT may be a feasible treatment option for T-LBL, even in the era of leukemia-type initial therapy.
format	article
author	Mari Morita-Fujita Yasuyuki Arai Satoshi Yoshioka Takayuki Ishikawa Junya Kanda Tadakazu Kondo Takashi Akasaka Yasunori Ueda Kazunori Imada Toshinori Moriguchi Kazuhiro Yago Toshiyuki Kitano Akihito Yonezawa Masaharu Nohgawa Akifumi Takaori-Kondo Kyoto Stem Cell Transplantation Group (KSCTG)
author_facet	Mari Morita-Fujita Yasuyuki Arai Satoshi Yoshioka Takayuki Ishikawa Junya Kanda Tadakazu Kondo Takashi Akasaka Yasunori Ueda Kazunori Imada Toshinori Moriguchi Kazuhiro Yago Toshiyuki Kitano Akihito Yonezawa Masaharu Nohgawa Akifumi Takaori-Kondo Kyoto Stem Cell Transplantation Group (KSCTG)
author_sort	Mari Morita-Fujita
title	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
title_short	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
title_full	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
title_fullStr	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
title_full_unstemmed	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
title_sort	indication and benefit of upfront hematopoietic stem cell transplantation for t-cell lymphoblastic lymphoma in the era of all-type induction therapies
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/33bb1f49f6f144e8930823840ad60891
work_keys_str_mv	AT marimoritafujita indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT yasuyukiarai indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT satoshiyoshioka indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT takayukiishikawa indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT junyakanda indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT tadakazukondo indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT takashiakasaka indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT yasunoriueda indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT kazunoriimada indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT toshinorimoriguchi indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT kazuhiroyago indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT toshiyukikitano indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT akihitoyonezawa indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT masaharunohgawa indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT akifumitakaorikondo indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies AT kyotostemcelltransplantationgroupksctg indicationandbenefitofupfronthematopoieticstemcelltransplantationfortcelllymphoblasticlymphomaintheeraofalltypeinductiontherapies
_version_	1718393851350089728

Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies

Ejemplares similares